AI phone app aims to ease cancer treatment side effects

NCT ID NCT07553572

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether an AI-powered smartphone app called ASSIST can help people with breast cancer, lymphoma, or colorectal cancer manage symptoms while on systemic therapy. Sixty participants will either use the app for 12 weeks or receive standard care. The main goals are to see if patients find the app easy to use and if they like it.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ASSIST smartphone application (AI-based symptom management tool)
What this could lead to
If it works, this could provide a convenient way for cancer patients to get personalized support and better manage treatment side effects at home.
What could go wrong
This is a small pilot study (60 people) focused on feasibility, not on proving the app improves health outcomes. It may not show clear benefits or be suitable for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER (LOCALLY ADVANCED OR METASTATIC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital

    RECRUITING

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.